Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes

This article was originally published in The Tan Sheet

Executive Summary

FDA's June 20 approval of Procter & Gamble/ AstraZeneca's Prilosec OTC permits the companies to sell the proton pump inhibitor in packages containing more than one 14-day treatment regimen
Advertisement

Related Content

Rx-to-OTC Switch Interest Explodes Following Deal Activity - Experts
Behind-The-Counter Sale Works Without Regulation – Former FDA Counsel
Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues
TAP Licenses Prevacid To Novartis For 2009 Switch
Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
Prilosec OTC Patent Extension Submission Pending At PTO
Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices
Prilosec OTC Heats Up Heartburn Sector; Competitors Set Sights On Launch
Rx-Strength Pepcid Could Join Prilosec OTC In Consumer Market
Aetna post-Claritin

Topics

Advertisement
UsernamePublicRestriction

Register

PS095613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel